Ruth E Langley

Summary

Affiliation: National Institute for Medical Research
Country: UK

Publications

  1. ncbi Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01
    Ruth E Langley
    Department of Oncology, University College of London, UK
    J Clin Oncol 23:8322-30. 2005
  2. ncbi Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer
    Ruth E Langley
    Endocrinology and Metabolic Medicine, Imperial College, London, UK
    BJU Int 102:442-5. 2008
  3. ncbi Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
    R E Langley
    MRC Clinical Trials Unit, London, UK
    Br J Cancer 105:1107-13. 2011
  4. ncbi Potential pitfalls in the design and reporting of clinical trials
    Matthew R Sydes
    Cancer Group, Medical Research Council Clinical Trials Unit, London, UK
    Lancet Oncol 11:694-700. 2010
  5. ncbi Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer
    William H Allum
    Department of Surgery, Royal Marsden National Health Services Foundation Trust, London, UK
    J Clin Oncol 27:5062-7. 2009
  6. ncbi Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    David Cunningham
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 355:11-20. 2006
  7. ncbi The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397)
    David P Dearnaley
    Institute of Cancer Research and Royal Marsden Hospitals, Sutton, UK
    Radiother Oncol 83:31-41. 2007
  8. ncbi Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)
    Malcolm D Mason
    Velindre Hospital, Department of Oncology and Palliative Medicine, School of Medicine, Cardiff University, Cardiff, UK
    J Natl Cancer Inst 99:765-76. 2007

Detail Information

Publications8

  1. ncbi Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01
    Ruth E Langley
    Department of Oncology, University College of London, UK
    J Clin Oncol 23:8322-30. 2005
    ..To compare the effectiveness and tolerability of epirubicin and paclitaxel (EP) with epirubicin and cyclophosphamide (EC) as first-line chemotherapy for metastatic breast cancer (MBC)...
  2. ncbi Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer
    Ruth E Langley
    Endocrinology and Metabolic Medicine, Imperial College, London, UK
    BJU Int 102:442-5. 2008
    ..To assess the hormonal effects of Fem7 (Merck, KGaA, Darmstadt, Germany) 100 microg transdermal oestrogen patches on men undergoing first-line androgen-deprivation therapy for prostate cancer...
  3. ncbi Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
    R E Langley
    MRC Clinical Trials Unit, London, UK
    Br J Cancer 105:1107-13. 2011
    ....
  4. ncbi Potential pitfalls in the design and reporting of clinical trials
    Matthew R Sydes
    Cancer Group, Medical Research Council Clinical Trials Unit, London, UK
    Lancet Oncol 11:694-700. 2010
    ..The areas covered include: assessing the scientific idea; trial design; size and duration of the trial; analysis; and reporting and presentation...
  5. ncbi Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer
    William H Allum
    Department of Surgery, Royal Marsden National Health Services Foundation Trust, London, UK
    J Clin Oncol 27:5062-7. 2009
    ..Initial results reported in 2002 demonstrated an advantage for both disease-free and overall survival in the CS group. The analysis has now been updated after a median follow-up of 6 years...
  6. ncbi Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    David Cunningham
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 355:11-20. 2006
    ..We assessed whether the addition of a perioperative regimen of ECF to surgery improves outcomes among patients with potentially curable gastric cancer...
  7. ncbi The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397)
    David P Dearnaley
    Institute of Cancer Research and Royal Marsden Hospitals, Sutton, UK
    Radiother Oncol 83:31-41. 2007
    ..Conformal radiotherapy (CFRT) raises the possibility that radiotherapy doses can be increased and long-term efficacy outcomes improved, with safety an important consideration...
  8. ncbi Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)
    Malcolm D Mason
    Velindre Hospital, Department of Oncology and Palliative Medicine, School of Medicine, Cardiff University, Cardiff, UK
    J Natl Cancer Inst 99:765-76. 2007
    ..Adjuvant bisphosphonate treatment improves outcomes of patients with bone metastasis-negative breast cancer, but the effects of bisphosphonates on bone metastases in prostate cancer are not known...